Stakeholder perspectives of the clinical utility of pharmacogenomic testing in solid organ transplantation
| Autor: | Jacinda N. Tran, Heather Anderson, Gordon K Young, Jan D. Hirsch, Christina L. Aquilante, Robert L. Page, Yee Ming Lee, Shirley M. Tsunoda, Kimberly M. Deininger |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Health Knowledge Attitudes Practice Health Personnel Pharmacogenomic Testing Qualitative property 030226 pharmacology & pharmacy 03 medical and health sciences 0302 clinical medicine Health care Genetics medicine Humans Precision Medicine Intensive care medicine Pharmacology business.industry Stakeholder Organ Transplantation Focus group Kidney Transplantation Liver Transplantation Pharmacogenetics 030220 oncology & carcinogenesis Pharmacogenomics Molecular Medicine Heart Transplantation Personalized medicine business Qualitative research |
| Zdroj: | Pharmacogenomics. 20(18) |
| ISSN: | 1744-8042 |
| Popis: | Aims: To assess stakeholder perspectives regarding the clinical utility of pharmacogenomic (PGx) testing following kidney, liver, and heart transplantation. Methods: We conducted individual semi-structured interviews and focus groups with kidney, liver, and heart transplantation patients and providers. We analyzed the qualitative data to identify salient themes. Results: The study enrolled 36 patients and 24 providers. Patients lacked an understanding about PGx, but expressed interest in PGx testing. Providers expressed willingness to use PGx testing, but reported barriers to implementation, such as lack of knowledge, lack of evidence demonstrating clinical utility, and patient healthcare burden. Conclusion: Patient and provider educational efforts, including foundational knowledge, clinical evidence, and applications to patient care beyond just immunosuppression, may be useful to facilitate the use of PGx testing in transplant medicine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|